Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA

被引：1
|
作者：
Lisberg, A. [1 ]
Bornazyan, K. [1 ]
Madrigal, J. [1 ]
Bui, J. [1 ]
Carroll, J. [1 ]
Adame, C. [1 ]
Hunt, J. [1 ]
Lu, H. [1 ]
Noor, Z. [1 ]
Cummings, A. [1 ]
Goldman, J. W. [1 ]
Garon, E. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
NSCLC; anti-PD-1; therapy; Thyroid;
D O I：
10.1016/j.jtho.2017.11.097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-038
引用
收藏
页码：S2430 / S2430
页数：1
相关论文
共 42 条
  • [21] 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
    Felip, Enriqueta
    Hellmann, Matthew David
    Hui, Rina
    Carcereny, Enric
    Leighl, Natasha B.
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Jensen, Erin
    Kush, Debra A.
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Exposure-response analysis of pembrolizumab in patients with advanced melanoma and non-small cell lung cancer enrolled in KEYNOTE-001,-002 and-006
    Chatterjee, Manash S.
    Turner, David C.
    Ahamadi, Malidi
    de Greef, Rik
    Freshwater, Tomoko
    Mayawala, Kapil
    Dong, David
    Stone, Julie
    de Alwis, Dinesh
    Kondic, Anna
    CANCER RESEARCH, 2016, 76
  • [23] Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities-a commentary of the 3-year follow-up of the KEYNOTE-001 trial
    Russo, Alessandro
    Scilla, Katherine A.
    Rolfo, Christian
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S598 - S602
  • [24] Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
    Oh, Do-Youn
    Algazi, Alain
    Capdevila, Jaume
    Longo, Federico
    Miller, Jr Wilson
    Bing, Jerry Tan Chun
    Eduardo Bonilla, Carlos
    Chung, Hyun Cheol
    Guren, Tormod K.
    Lin, Chia-Chi
    Motola-Kuba, Daniel
    Shah, Manisha
    Hadoux, Julien
    Yao, Lili
    Jin, Fan
    Norwood, Kevin
    Lebellec, Loic
    CANCER, 2023, 129 (08) : 1195 - 1204
  • [25] Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
    Leigh, Natasha B.
    Hellmann, Matthew D.
    Hui, Rina
    Carcereny, Enric
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani S.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (04): : 347 - 357
  • [26] Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
    Garon, Edward B.
    Hellmann, Matthew D.
    Rizvi, Naiyer A.
    Carcereny, Enric
    Leighl, Natasha B.
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani S.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew
    Ramalingam, Suresh S.
    Felip, Enriqueta
    Goldman, Jonathan W.
    Scalzo, Cathie
    Jensen, Erin
    Kush, Debra A.
    Hui, Rina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (28) : 2518 - +
  • [27] Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
    Garon, Edward B.
    Hellmann, Matthew David
    Costa, Enric Carcereny
    Leighl, Natasha B.
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Felip, Enriqueta
    Scalzo, Cathie
    Jensen, Erin
    Kush, Debra A.
    Hui, Rina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [28] Prognostic Variables Associated with Improved Outcomes in Stage III NSCLC Patients Treated with Consolidation Pembrolizumab
    Anouti, B.
    Althouse, S.
    Durm, G.
    Breen, T.
    Hanna, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S627 - S627
  • [29] Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
    Gadgeel, Shirish
    Gray, Jhanelle E.
    Rizzo, Maria Teresa
    Peterson, Patrick
    Kim, Jong Seok
    Rodriguez-Abreu, Delvys
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
  • [30] Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.
    Robert, Caroline
    Joshua, Anthony M.
    Kefford, Richard
    Joseph, Richard Wayne
    Wolchok, Jedd D.
    Hodi, F. Stephen
    Hamid, Omid
    Weber, Jeffrey S.
    Gangadhar, Tara C.
    Dronca, Roxana Stefania
    Patnaik, Amita
    Zarour, Hassane M.
    Hwu, Wen-Jen
    Hersey, Peter
    Daud, Adil
    Giannotti, Maxine
    Li, Xiaoyun Nicole
    Ebbinghaus, Scot
    Kang, Soonmo Peter
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345